SAP scan

SAP scan images showing progression of AL amyloidosis kidney and liver involvement following chemotherapy

A SAP scan is a type of nuclear medicine imaging test which uses iodine-123 (123I) and serum amyloid P component (SAP) to diagnose amyloidosis.[1][2]

In patients with amyloidosis, large deposits of SAP coat the affected organs, in addition to the low levels normally found in the blood stream.[3] The injected 123I-SAP localises specifically to amyloid deposits, showing up as hot spots in the image.[4]

Procedure

The radiopharmaceutical is injected into the patient, with imaging taking place on a gamma camera 6-24 hours later.[3] An early blood-pool image provides a baseline for comparison with the organ SAP uptake after 24 hours.[4]

Availability

Europe

123I-SAP was granted orphan designation by the European Medicines Agency in 2003, however this was withdrawn in 2016.[5]

SAP scanning is only carried out at two European centres; in the United Kingdom from the National Amyloidosis Centre, based at the Royal Free Hospital,[6] and in the Netherlands at University Medical Center Groningen.[7]

North America

SAP scanning is not approved in the United States due to its use of human blood products.[7]

See also

References

  1. Lass, Piotr (2014). "Nuclear imaging of amyloidosis". Polish Journal of Radiology. 79: 222–227. doi:10.12659/PJR.890147. PMC 4111651.
  2. Sachchithanantham, S.; Wechalekar, A. D. (29 July 2013). "Imaging in systemic amyloidosis". British Medical Bulletin. 107 (1): 41–56. doi:10.1093/bmb/ldt021. PMID 23896486.
  3. 1 2 "The SAP scan (AL amyloidosis)". Myeloma UK. Retrieved 28 July 2019.
  4. 1 2 Sachchithanantham, S.; Wechalekar, A. D. (29 July 2013). "Imaging in systemic amyloidosis". British Medical Bulletin. 107 (1): 41–56. doi:10.1093/bmb/ldt021. PMID 23896486.
  5. "EU/3/03/134 - Iodine (123I) Serum Amyloid P". European Medicines Agency. 17 September 2018. Retrieved 28 June 2019.
  6. "NHS STANDARD CONTRACT FOR DIAGNOSTIC SERVICE FOR AMYLOIDOSIS" (PDF). NHS England. 2013. Retrieved 28 June 2019.
  7. 1 2 Noordzij, Walter; Glaudemans, Andor W. J. M.; Slart, Riemer H. J. A.; Dierckx, Rudi A.; Hazenberg, Bouke P. C. (22 August 2012). "Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis". Amyloid. 19 (4): 208–211. doi:10.3109/13506129.2012.717993. PMID 17504868.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.